← All stocks

Vertex Pharmaceuticals

VRTX Scheduled selling only
CIK 0000875320 #469 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$158.38M
$65.56M on a plan · $92.82M straight out of an exercise
Sold at will
$0.00
0 of 94 sales
Net
−$158.38M
$0.00 against sales at will

By person

23 insiders · 95 transactions
31.8×

Reshma Kewalramani holds 31.8 times base salary in stock. $51.01M of shares against $1.60M in salary for 2025.

Salary from the company's own proxy. The shares are what Reshma Kewalramani last reported holding, valued at $519.00, the price Common Stock was last bought or sold at on the open market here, on 2 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
LEIDEN JEFFREY M
Executive Chairman
$60.94M (17) scheduled
−$60.94M
34,797
0.0137%
$18.06M
+248.2%
Sachdev Amit
EVP Chief Patient & Ext Af Off
$28.38M (9) scheduled
−$28.38M
66,512
0.0262%
$34.52M
+31.0%
Kewalramani Reshma
CEO & President
$19.74M (13) scheduled
−$19.74M
98,278
0.0388%
$51.01M
+8.0%
Bozic Carmen
EVP and CMO
$11.31M (10) scheduled
−$11.31M
15,337
0.0061%
$7.96M
−34.1%
WAGNER CHARLES F JR
EVP, CO & FO
$10.78M (3) scheduled
−$10.78M
47,042
0.0186%
$24.41M
−0.3%
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
$6.51M (8) scheduled
−$6.51M
53,572
0.0211%
$27.80M
+8.9%
McKechnie Duncan
EVP, Chief Commercial Officer
$5.66M (5) scheduled
−$5.66M
11,001
0.0043%
$5.71M
−32.1%
Biller Jonathan
EVP and Chief Legal Officer
$4.08M (7) scheduled
−$4.08M
13,659
0.0054%
$7.09M
−25.3%
Atkinson Edward Morrow III
EVP, Chief Technical Ops. Off.
$3.60M (5) scheduled
−$3.60M
18,432
0.0073%
$9.57M
+15.4%
Bunnage Mark E.
EVP, Chief Scientific Officer
$3.00M (5) scheduled
−$3.00M
7,284
0.0029%
$3.78M
−54.7%
Liu Joy
EVP and Chief Legal Officer
$2.13M (5) scheduled
−$2.13M
19,131
0.0075%
$9.93M
−19.5%
Ambrose Kristen
SVP & Chief Accounting Officer
$1.98M (5) scheduled
−$1.98M
11,624
0.0046%
$6.03M
+55.0%
Bhatia Sangeeta N.
Director
$267.75K (2) scheduled
−$267.75K
4,924
0.0019%
$2.56M
+11.0%
Arbuckle Stuart A
EVP, COO
63,368
0.0250%
$32.89M
+27.4%
SACHS BRUCE I
Director
39,000
0.0154%
$20.24M
−2.5%
ALTSHULER DAVID
EVP, Chief Scientific Officer
34,477
0.0136%
$17.89M
+33.2%
van Grunsven Jasper
EVP, CP and NPPO
8,682
0.0034%
$4.51M
Garber Alan M
Director
7,344
0.0029%
$3.81M
+13.4%
CARNEY LLOYD
Director
6,315
0.0025%
$3.28M
−0.1%
MCKENZIE DIANA
Director
2,378
0.0009%
$1.23M
−2.4%
Thornberry Nancy
Director
2,109
0.0008%
$1.09M
+28.8%
Upadhyay Suketu
Director
1,558
0.0006%
$808.60K
−39.1%
Schneider Jennifer
Director
1,394
0.0005%
$723.49K
+51.2%
Insider
Date
Role
Action
Shares
Price
Amount
LEIDEN JEFFREY M
4 Dec 2025
Executive Chairman
Exercised, kept
1
$91.05
$91.05

What was left out

Form 4 filings counted 110
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 68
Sales straight out of an exercise 26
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 548,576
History held since 2 Sep 2016